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Objective: This trial was conducted to evaluate the effectiveness of oral hypoglycemic agents on diabetic control 
and biochemical parameters of known diabetic subjects. 
Introduction: T2DM occurs due to abnormal metabolism of carbohydrates, proteins, and lipids leading to 
increased blood glucose characterized by polyuria and polydipsia due to relative5 deficiency or lack of insulin. 
Besides dietary control and insulin therapy, various oral hypoglycemic such as sulfonylurea biguanide, a 
thiazolidinedione, DPP–4 inhibitors, glucagon-like peptide inhibitors, and SGL2.  
Material and Methods: This comparative trial was carried out on previously diagnosed type–2 diabetic subjects. 
This trial was conducted at health care centers of District Nowshehra viz. NMC Nowshehra, DHQ Hospital 
Nowshehra, and ICS, Peshawar in collaboration with KMC and PIMC Peshawar, Khyber Pakhtunkhwa, Pakistan. 
A total of 200 known diabetic subjects were randomly recruited based on predetermined selection criteria and 
were split into two groups.  
Results: Significant results (p < 0.05) were seen for glycemic control (FBS, RBS, HbA1C) in Group B as compared 
to Group A patients. 
Keywords: Anti-diabetic, HbA1C, Sulfonylurea, DPP–4 Inhibitors 
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Introduction 
 
Type–2 diabetes (T2DM) occurs due to abnormal 
metabolism of carbohydrates, proteins, and lipids 
leading to increased blood glucose characterized by 
polyuria and polydipsia due to relative deficiency or 
lack of insulin.1 T2DM, previously called NIDDM 
account for up to 90–95 % of diabetes. Type–2 diabetes 
is an islet paracrinopathy in which mutual connection 
exists between alpha cells (secrete glucagon) and beta 
cells (secrete insulin) is abolished which causes 
increased blood glucose level (hyperglycemia).2,3 Poor 
or deficient insulin production increases glycogen 
breakdown from glucose. In diabetes level of glucose 
is increased so more influx of glucose occurs than 
outflow. Abnormal functioning of islet cells is an 
important character of type–2. In type–2 diabetes 
increased hepatic glucose production occurs due to 
hypersecretion of glucagon.4 In obese type–2 diabetic 
patients insulin resistance is increased in the liver, 
muscles, adipose tissue, myocardium, overproduction, 
and underutilization of glucose occurs.5 According to 
the International Diabetes Federation (IDF) known 
patients of type–2 diabetes were 336 million in 2011 
and this number will exceed up to 552 million by 
2030.6 
Obesity and overweight are major risk factors for 
metabolic syndrome which is an important bunch of 
coronary heart disease (CAD) risk factors, like high 
blood pressure, diabetes mellitus, and dyslipidemia.7–9 
A large number of research studies have revealed that 
subjects with deranged metabolism are at a high risk 
of future development of type–2 diabetes mellitus.10,11 
T2DM is strongly associated with overweight and 
obesity.12,13 A positive link between body mass indexes 
(BMI), lipids, glucose, and blood pressure have been 
formerly reported.14–16 The death rate in diabetic 
individuals is 2 times more than individuals of the 
same age.17 In 2015 in the US diabetes is the l7th 
leading cause of death.18 Discovery of insulin in the 
19th century comprised as a milestone for the control of 
glucose. Various oral hypoglycemic agents such as 
sulfonylurea, biguanide, thiazolidinedione, DPP–4 
Inhibitors, glucagon-like peptide (GLP–1 Inhibitors), 
and SGL2 (Sodium Potassium Co–transport Inhibitors) 
are used to treat T2DM. DPP–4 inhibitors act by 
breaking down peptides like glucose-dependent 
insulinotropic polypeptide (GIP) and GLP–1. DPP–4 
inhibitors (discovered in 1966) are used as 
monotherapy or it can be used also with biguanide or 
with a thiazolidinedione. All drugs in this class are 
weight neutral. Common drugs of this class are 
Sitagliptin, Vildagliptin, Saxagliptin, and Linagliptin19. 
Biological engrossment for the use of dipeptidyl 
peptidase escalates after acquiescence of DDP–4 
inhibitors as pharmacological agents for the treatment 
of type–2 diabetes. Many reviews have enlightened the 
effectiveness of using DPP–4 inhibitors as a treatment 
therapy for type–2 diabetes13. DPP–4 inhibitors are 
renal and cardiac friendly20-23. Biguanide is an oral 
hypoglycemic drug acting by decreasing peripheral 
insulin resistance decreases morbidity and mortality in 
T2DM. Further studies illustrated sustained glucose 
control in diabetic subjects treated with DPP–4 
inhibitors alone or in combination with biguanide.24 
 
Materials and Methods 
 
This comparative study was carried out on previously 
diagnosed type–2 diabetic subjects. This study was 
conducted at health care centers of District Nowshehra 
viz. Nowshehra Medical Complex (NMC) Nowshehra, 
District Head Quarter (DHQ) Hospital Nowshehra, 
and Institute of Chemical Science (ICS), Peshawar in 
collaboration with Khyber Medical College and Pak 
International Medical College (PIMC), Peshawar, 
Khyber Pakhtunkhwa (KPK), Pakistan. A total of 200 
known diabetic subjects were randomly recruited 
based on predetermined selection criteria and were 
divided into two groups. The first group (Group A) 
having 100 diabetic subjects was given DPP–4 
inhibitor; Sitagliptin 50 mg two times a day alone for 
six (06) months while the second group (Group B) 
comprising of 100 patients were treated with a 
combination of DPP–4 inhibitor (Sitagliptin 50 mg 1 
BD) and metformin in a dose of 500 mg two times a 
day. Venous blood samples were taken from all 
participants in both fasting (10–12 hour night long fast) 
and random (2 hours post-prandial) state. FBS, RBS, 
HbA1C, S. creatinine, blood urea, fasting lipid profile, 
and serum electrolytes were determined by 
spectrophotometric colorimetric methods using kits 
(procured from Elitech, Spain) at 03 and 06 months 
follow up.  LDL–c was determined by Fried Wald’s 
formula. Inclusion criteria were that patients with 
T2DM of age 18years and above were included. T2DM 
patients on insulin, diabetic nephropathy, and 
retinopathy were excluded. The study was approved 
by the Ethical Board of the University of Peshawar. 
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Results 
 
Table 1 reveals the correlation of various demographic 
parameters and highly significant differences (p < 
0.001) were found for age, BMI, SBP, and pulse 
respectively. Table 2 reveals the effects of the use of 
anti-diabetic drug DPP–4 inhibitors alone. The Mean + 
SD results show that the fasting blood glucose level 
was notably changed (p<0.07) at the end of 6-month 
drug therapy. The data further reveals that the level of 
high-density lipoproteins in diabetic individuals rises 
again after the use of hypoglycemic agents (DPP–4 
alone) for six months or more and the dissimilarity 
was outstanding (p<0.03). Similar findings were 
obtained for blood urea (p<0.07). 
 
Table 1: General Characteristics and Various Demographic Parameters (Means+SD) of Study Subjects 
Parameters Group A (n=100) Group B (n=100) p-value 
Age (Years) 52.50+11.80 59.00+15.70 0.002 
BMI ( Kg/m2 ) 32.25+6.68 27.94+5.21 0.000 
SBP ( mmHg ) 127.60+19.80 119.39+7.45 0.000 
DBP ( mmHg ) 81.00+10.67 79.00+8.01 0.130 
Pulse 90.00+2.80 85.00+9.52 0.000 
Heart Rate 68.00+3.22 67.00+1.33 0.471 
Values are given as mean +SD 
 
Table 2: The Effect of Use of Dipeptidyl Peptidase–4 (DPP–4) Inhibitors alone on Biochemical Parameters 
(Group A) 
Biochemical Parameter Baseline 03 Months p–values 6 Months p–values 
FBS (mg/dL)  189.33+82.95 142.67+47.86 0.26 113.33+40.86 0.07 
RBS (mg/dL)  402.83+115.80 333.33+134.71 0.36 267.00+170.2 0.13 
HbA1C  9.00+3.45 8.50+3.45 0.03 7.00+2.92 0.05 
Lipid Profile 
Cholesterol (mg/dL)  211.67+38.68 182.50+19.42 0.13 147.50+81.59 0.11 
Triglycerides (mg/dL)  205.33+148.41 135.00+62.53 0.31 129.00+70.48 0.28 
HDL–c   (mg/dL)  39.00+5.44 40.67+3.44 0.05 43.33+5.57 0.03 
LDL–c  (mg/dL)  127.26+32.96 121.50+17.37 0.49 90.05+69.61 0.17 
Renal Profile 
Urea (mg/dL)  50.33+16.50 33.33+14.12 0.08 36.67+4.17 0.07 
S. Creatinine (mg/dL)  1.35+0.50 1.18+0.39 0.50 1.00+0.154 0.12 
Serum Electrolytes 
Na+ (m mol/L) 138.00+5.65 136.00+0.00 0.40 139.33+4.50 0.66 
K+  (m mol/L) 4.41+0.57 3.75+1.66 0.37 4.28+0.57 0.69 
Values are given as mean +SD 
Table 3 represents the effects of the use of combination 
drugs (DPP–4 inhibitor (Sitagliptin 50 mg 1 BD) and 
metformin in a dose of 500 mg two times a day) on 
biochemical parameters of diabetic subjects from 
baseline to 6 months duration of treatment. Mean+SD  
fasting blood sugar of diabetic individuals at the start, 
at after three (03) and six (06) months were found to be 
145.40+56.92, 125.40+35.63 and 100.40+22.80 mg/dL 
respectively and insignificant change in the result  
(p>0.05) was observed for at the end of three months. 
However, the difference was highly outstanding 
(p<0.001) in the case of RBS after 6 months of 
combination drug therapy. The mean+SD HbA1C at 
the start after three and six months of treatment was 
found to be 8.25+1.91, 7.50+1.65, and 6.00+1.46, and 
the change was significant (p<0.05). A highly 
significant change (p < 0.00) was observed for serum 
total cholesterol HDL–c and LDL–c after six months 
duration of treatment with DPP–4 and metformin it 
was non–significant change (p>0.05) for TG. Mean+SD 
of blood urea of diabetic individuals at the start and 
following three and six months therapies were 
32.80+5.49, 28.20+4.26, and 27.50+5.75 mg/dL 
respectively and insignificant change (p > 0.05) was 
noted. Similarly, mean+SD of serum creatinine at 
baseline, three and six months therapies were 
1.20+0.31, 1.12+0.39, and 0.86+0.25 mg/dL, and 
significant difference (p<0.05) was noted. Contrast 
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results were obtained in the case of serum electrolytes especially serum potassium levels in the instant study. 
 
Table 3: The Effect of Use of Combination Drugs (Dipeptidyl Peptidase–4 Inhibitors + Metformin) (Group B) 
Biochemical Parameter Baseline 03 Months p–values 6 Months p–values 
FBS (mg/dL)  145.40+56.92 125.40+35.63 0.35 100.40+22.80 0.03 
RBS (mg/dL)  308.30+75.50 249.80+66.03 0.08 186.50+66.51 0.00 
Hb A1c  8.25+1.91 7.50+1.65 0.55 6.00+1.46 0.019 
Lipid Profile 
S. Total Cholesterol (mg/dL)  202.00+30.11 180.00+28.75 0.91 130.00+29.48 0.00 
Triglyceride (mg/dL)  143.50+27.29 136.50+46.55 0.68 111.00+25.14 0.01 
HDL–c   (mg/dL)  38.40+6.51 43.70+6.21 0.07 44.80+4.89 0.04 
LDL–c   (mg/dL)  129.60+28.11 134.90+27.81 0.67 102.00+24.01 0.00 
Renal Profile 
Urea (mg/dL) 32.80+5.49 28.20+4.26 0.05 27.50+5.75 1.00 
S. Creatinine (mg/dL)  01.20+0.31 01.12+0.39 0.61 0.86+0.25 0.01 
Serum Electrolytes 
Na+ (m mol/L) 135.70+1.56 137.80+2.89 0.05 138.90+3.63 0.02 
K+  (m mol/L) 04.40+0.44 04.29+0.51 0.61 04.30+0.56 0.66 




Dipeptidyl peptidase–4 inhibition decreases glucose 
levels and enhances beta cells’ function and decreases 
glucagon level, increased intact glucagon-like–
peptide–1 (GLP-1), and glucose-dependent 
insulinotropic polypeptide (GIP). DPP–4 inhibitors 
control hyperglycemia in type–2 diabetes by affecting 
fasting as well as postprandial glucose.25 The results of 
our study are congruous with the studies mentioned 
above. Verities of DPP–4 inhibitors exist26, and they 
decrease the HbA1C by ≈ 5–10 mmol/L in dual 
therapy (when added to metformin) and in 
monotherapy in studies over 6 months. Better 
glycemic control is attained by inactivation of the 
DPP4 enzyme that inhibits incretin hormones (GLP-1 
and GIP ).27 DPP–4 inhibition decreases glycemia 
sustainably. Furthermore, the reduction in glucagon 
after DPP–4 inhibition illustrated the chief mechanism 
supporting the improvement in glycaemia28. The DPP–
4 inhibitor varies in its structure and enzyme binding 
characters and pharmacokinetics. The effectiveness 
degree of DPP–4 inhibition varies between DPP–4 
inhibitors however inhibition is sustained at 70 to 90% 
over 24 hours after drug administration.28 DPP–4 
inhibitor is comprised of various types i.e. Alogliptin 
that affects improving insulin resistance when used in 
dual therapy with another hypoglycemic agent.29–31  
Dipeptidyl Peptidase–4 is a class of drugs that reduces 
the inactivation of GLP–1 and GIP which increases the 
synthesis of insulin and decreases glucagon release by 
pancreatic cells. Glycemic effectiveness is achieved 
when both DPP–4 and biguanide are used together. 
The same result was also noted by Sharma M et al., 
(2017)32 and Jain R (2015)33 respectively, and thus are 
in agreement with our results. Our observations 
regarding glycemic control by the use of DPP–4 as 
monotherapy was almost similar to that of 
sulfonylurea (as monotherapy) and is in accordance 
with the findings reported by Sharma M and 
coworkers (2017)32 however they instead of 
monotherapy used dual therapy (DPP–4 and 
Biguanide) and our results regarding dual therapy 
(DPP–4+Sulfonylurea) are almost comparable with the 
above.  
According to our research on hypoglycemic agents 
used up to six months in monotherapy most effective 
drugs are sulfonylurea followed by DPP–4 regarding 
the reduction in HbA1C however, the result was 
carried out by Amir. Q and coworkers (2017) on 
hypoglycemic control show that using sulfonylurea 
class drugs over DPP–4 reduces Hb A1C but it has 
contradictory with the results that biguanide falls on 
the second number as compared to DPP–4.34 
Effectiveness and protection of DPP–4 inhibitor 
combination treatment had been shown by numerous 
multicenter, non-specific, double-blind, placebo-
controlled studies.35 Alike prior studies that 
manifested that combination treatment of DPP–4 
inhibitor was secure and effective, the current survey 
indicated that the risks of severe hypoglycemia and 
death in patients dosed roughly with DPP–4 inhibitor 
in dual therapy were not different from those obtained 
with proper dosing of DPP–4 inhibitor as 
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monotherapy.36,37 To achieve much more effective 
results in controlling fasting and random blood 
glucose level and glycosylated hemoglobin we used 
combination therapy (dual therapy). Encouraging 
results were obtained in the case of dipeptidyl 
peptidase class along with sulfonylurea which reduces 
HbA1C concentration up to 2.25 from the results 
observed at baseline and the present results are in 





DPP–4 inhibition prevents hypoglycemia via increased 
glucagon counter-regulation through the incretin 
hormone glucose-dependent insulinotropic 
polypeptide. A combination of DPP–4 inhibitors with 
Biguanides has good glycemic control over DPP–4 
inhibitors as monotherapy in obese T2DM with fewer 
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